SALT LAKE CITY, April 08, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, announced today that in connection with the hiring of Mr. Donnelly as chief commercial officer, previously announced on April 7, 2025, the Board of Directors of Myriad Genetics authorized the grant to Mr. Donnelly of restricted stock units equal to $3.75 million, comprising (i) time-based restricted stock units (RSUs) equal to $2 million and (ii) performa ...

SALT LAKE CITY, April 07, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, announced today the appointment of Brian Donnelly as chief commercial officer (CCO), effective May 1, 2025. A strategic, results-oriented leader with more than 20 years of experience in healthcare, diagnostics, and medical technology, Donnelly has a proven track record of building and leading high-performing teams, managing multi-billion-dollar P&Ls, and ...

Myriad Genetics, Inc.’s (MYGN) Oncology growth strategy, which focuses on expanding companion diagnostics and market growth through new clinical guidelines, is poised to drive growth in the upcoming quarters. The company’s innovative product launches and upgrades look encouraging. Yet, unfavorable currency fluctuations and competitive disadvantages may hurt Myriad Genetics’ operations.In the past year, this Zacks Rank #3 (Hold) company’s shares have lost 56.8% compared with the industry’s 11.9% decline. The ...

Medical equipment stock Myriad Genetics Inc (NASDAQ:MYGN) was last seen up 9.8% at $11.25, after an upgrade from Piper Sandler to "overweight" from "neutral," with a price-target hike to $12.50 from $11.50. The firm noted an attractive entry point following the stock's extended pullback, and cited the CEO change, as Sam Raha will replace Paul Diaz on April 30. Today's surge builds on MYGN’s 6.8% gain in the previous session, following its March 10 five-year low of $9.24. The stock broke below support at $12 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________________________________________ FORM 10-K _______________________________________________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission file numbe ...

SALT LAKE CITY, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, today announced a collaboration with Gabbi, a telehealth solution for breast cancer risk assessment and specialist care services. The companies will work together to provide an integrated offering that combines Gabbi’s risk assessment program and access to breast specialists with Myriad’s MyRisk® with RiskScore® Hereditary Cancer Test. “After losing my mom ...

On Monday, in its earnings release, Myriad Genetics Inc. MYGN said Unitedhealth Group Inc’s UNH UnitedHealthcare will stop covering multi-gene panel pharmacogenetic testing, including Myriad Genetics’ GeneSight test, for its commercial, individual exchange, and certain managed Medicaid plans. This change takes effect in the first half of 2025.In 2024, Myriad Genetics earned about $45 million from GeneSight testing through UnitedHealthcare, with $40 million from commercial plans and $5 million from managed M ...

Myriad Genetics, Inc. (MYGN) reported fourth-quarter 2024 adjusted earnings of 3 cents per share, which came in line with the Zacks Consensus Estimate. The company reported earnings of 4 cents per share in the year-ago quarter.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.Adjusted earnings exclude amortization expenses from acquired intangible assets, equity compensations and real estate optimization. The GAAP loss was 47 cents compared with the prior-year quarter’s loss of 36 cents ...

Myriad Genetics, Inc. (NASDAQ:MYGN) Q4 2024 Results Conference Call February 24, 2025 4:30 PM ET Company Participants Matt Scalo - Senior Vice President of Investor Relations Paul Diaz - President and Chief Executive Officer Sam Raha - Chief Operating Officer Mark Verratti - Chief Commercial Officer Scott Leffler - Chief Financial Officer Conference Call Participants Madeline Mollman - Wolfe Research Will Ortmayer - Goldman Sachs Madison Pasterchick - Morgan Stanley Tycho Peterson - Jefferies Sung Ji Nam - ...

Group 1 - Myriad Genetics reported quarterly earnings of $0.03 per share, matching the Zacks Consensus Estimate, compared to $0.04 per share a year ago [1] - The company posted revenues of $210.6 million for the quarter ended December 2024, exceeding the Zacks Consensus Estimate by 0.22%, and up from $196.6 million year-over-year [2] - Myriad has surpassed consensus revenue estimates four times over the last four quarters [2] Group 2 - The stock's immediate price movement will depend on management's commentary during the earnings call [3] - Myriad shares have increased approximately 3.4% since the beginning of the year, outperforming the S&P 500's gain of 2.2% [3] Group 3 - The earnings outlook for Myriad is uncertain, with current consensus EPS estimates at breakeven on $212.75 million in revenues for the coming quarter and $0.09 on $859.09 million in revenues for the current fiscal year [7] - The estimate revisions trend for Myriad is currently unfavorable, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6] Group 4 - The Medical - Biomedical and Genetics industry is currently in the top 26% of Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions [5]